Verition Fund Management LLC boosted its position in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 130.7% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,152 shares of the company’s stock after purchasing an additional 2,352 shares during the period. Verition Fund Management LLC’s holdings in Henry Schein were worth $760,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in HSIC. BlackRock Inc. boosted its position in Henry Schein by 2,999.6% during the first quarter. BlackRock Inc. now owns 5,595,279 shares of the company’s stock valued at $951,028,000 after purchasing an additional 5,414,761 shares during the last quarter. Janus Henderson Group PLC boosted its position in Henry Schein by 394.1% during the second quarter. Janus Henderson Group PLC now owns 1,465,303 shares of the company’s stock valued at $268,173,000 after purchasing an additional 1,168,763 shares during the last quarter. MARSHALL WACE ASIA Ltd acquired a new stake in Henry Schein during the first quarter valued at $50,281,000. Marshall Wace North America L.P. acquired a new stake in Henry Schein during the first quarter valued at $50,281,000. Finally, Vanguard Group Inc. boosted its position in Henry Schein by 3.0% during the second quarter. Vanguard Group Inc. now owns 8,086,317 shares of the company’s stock valued at $1,479,959,000 after purchasing an additional 236,862 shares during the last quarter. 44.74% of the stock is owned by hedge funds and other institutional investors.

A number of analysts recently issued reports on HSIC shares. Credit Suisse Group reissued a “hold” rating and set a $87.50 price objective on shares of Henry Schein in a research report on Tuesday, August 29th. Piper Jaffray Companies raised Henry Schein from a “neutral” rating to an “overweight” rating in a research report on Friday, September 15th. Stifel Nicolaus reissued a “hold” rating on shares of Henry Schein in a research report on Thursday, July 6th. UBS AG reissued a “buy” rating on shares of Henry Schein in a research report on Friday, September 15th. Finally, Morgan Stanley started coverage on Henry Schein in a research report on Thursday, September 21st. They set an “equal weight” rating and a $88.00 price objective for the company. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and six have given a buy rating to the company’s stock. Henry Schein has a consensus rating of “Hold” and an average target price of $92.14.

ILLEGAL ACTIVITY NOTICE: This report was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://theolympiareport.com/2017/10/16/verition-fund-management-llc-grows-position-in-henry-schein-inc-hsic.html.

Shares of Henry Schein, Inc. (HSIC) traded up 0.51% during mid-day trading on Monday, hitting $81.34. The company’s stock had a trading volume of 117,840 shares. The stock has a market cap of $12.86 billion, a PE ratio of 23.77 and a beta of 1.09. Henry Schein, Inc. has a 1-year low of $73.11 and a 1-year high of $93.50. The company has a 50-day moving average price of $82.72 and a 200-day moving average price of $87.37.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, August 8th. The company reported $0.88 EPS for the quarter, topping the Zacks’ consensus estimate of $0.86 by $0.02. Henry Schein had a net margin of 4.59% and a return on equity of 19.91%. The company had revenue of $3.06 billion during the quarter, compared to the consensus estimate of $3.05 billion. During the same period in the prior year, the business posted $0.82 EPS. The company’s quarterly revenue was up 6.4% on a year-over-year basis. Analysts predict that Henry Schein, Inc. will post $3.64 EPS for the current fiscal year.

Henry Schein announced that its Board of Directors has initiated a stock buyback plan on Monday, September 18th that permits the company to repurchase $400.00 million in shares. This repurchase authorization permits the company to purchase up to 6.3% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its stock is undervalued.

In other news, SVP Paul Rose sold 2,126 shares of the stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $172.51, for a total transaction of $366,756.26. Following the completion of the transaction, the senior vice president now directly owns 17,841 shares in the company, valued at approximately $3,077,750.91. The transaction was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 1.19% of the company’s stock.

About Henry Schein

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC).

Institutional Ownership by Quarter for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.